Biocon Banks on Weight-Loss Drugs, Ups Biosimilar Stake
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
Discover why revolutionary weight-loss drugs aren't magic bullets for India's obesity crisis. Learn about limitations, costs, and sustainable solutions.
Bengaluru medical experts sound alarm on diabetes drugs being misused for weight loss, highlighting dangerous side effects and long-term health risks.